| Literature DB >> 34177177 |
Isabella Princess1, Rohit Vadala2.
Abstract
We live in an era of evolving microbial infections and equally evolving drug resistance among microorganisms. In any healthcare facility, intensivists play the most pivotal role with critically ill patients under their direct care. Majority of the critically ill patients already harbor a microorganism at admission or acquire one in the form of healthcare-associated infections during their course of intensive care unit stay. It is therefore rather imperative for intensivists to possess sound knowledge in clinical microbiology. On a negative note, most clinicians have very meager and remote knowledge acquired during their undergraduate years. This knowledge is rather theoretical than applied and wanes over the years becoming nonbeneficial in intensive patient care. We, therefore, intend to explore important concepts in applied microbiology and infection control that intensivists should know and implement in their clinical practice on a day-to-day basis. How to cite this article: Princess I, Vadala R. Clinical Microbiology in the Intensive Care Unit: Time for Intensivists to Rejuvenate this Lost Art. Indian J Crit Care Med 2021;25(5):566-574.Entities:
Keywords: Antibiogram; Antibiotics; Critical care; Immunoprophylaxis; Intensivist; Knowledge; Microbiology; Microorganisms; Outbreaks
Year: 2021 PMID: 34177177 PMCID: PMC8196372 DOI: 10.5005/jp-journals-10071-23810
Source DB: PubMed Journal: Indian J Crit Care Med ISSN: 0972-5229
Prevalence of ESBL and CRE colonization during hospitalization
| Azim et al.[ | India, 2010 | 59–63% | 10–16% |
| McConville et al.[ | USA, 2017 | 28% (Either ESBL or CRE) | |
| Salomao et al.[ | Brazil, 2017 | – | 6.8% |
| Kaarme et al.[ | Sweden, 2018 | 16.8% | – |
| Pilmis et al.[ | France, 2018 | 17.7% | – |
| Ramanathan et al.[ | Chennai, 2018 | – | 7.8% |
| Goodman et al.[ | USA, 2018 | – | 3.9% |
| Mahamat et al.[ | Chad-Central Africa, 2019 | 44.5% | – |
| Hagel et al.[ | Germany, 2019 | 12.7% | – |
Clinical profile of unusual pathogens encountered in ICUs[56]
| Meningococcemia | Petechaie/purpura, shock, bilateral adrenal hemorrhage, meningitis, disseminated intravascular coagulation, multiorgan failure. | |
| Melioidosis | Risk factors: diabetes mellitus, alcoholism. | |
| Diphtheria | Faucial diphtheria: pseudomembrane adherent to mucosal base and bleeds on removal, bull neck. | |
| Anthrax | Cutaneous/pulmonary (hemorrhagic pneumonia)/gastrointestinal anthrax. | |
| Nocardiosis | Pulmonary (lobar pneumonia), disseminated. | |
| Brucellosis | Triad: fever with profuse night sweats, arthralgia/arthritis, hepatosplenomegaly. | |
| Leptospirosis | Weil's disease—hemorrhages, jaundice, and renal failure. | |
| Scrub typhus | Triad: eschar, regional lymphadenopathy, maculopapular rash | |
| Strongyloidiasis | Hyperinfection syndrome (colitis, enteritis, and malabsorption), disseminated strongyloidiasis. | |
| Amoebic encephalitis | Primary amoebic meningoencephalitis—acute suppurative infection of central nervous system, changes in taste and smell (olfactory nerve involvement). | |
| Rabies | Encephalitis, autonomic dysfunction (increased salivation, lacrimation, perspiration, and cardiac arrhythmia), hydrophobia, aerophobia, flaccid paralysis (quadriparesis with facial palsy) | |
| Viral hemorrhagic fever | Crimean–Congo hemorrhagic fever, Nipah, etc. | Contact with wild animals/mammals, fever, headache, myalgia, vomiting, diarrhea, rash with hemorrhages (bleeding or bruise), shock. |
| Cryptococcosis | Pulmonary cryptococcosis, cryptococcal meningitis, skin lesions, osteolytic bone lesions. | |
| Histoplamosis | Pulmonary granulomas, skin and oral lesions, disseminated histoplasmosis. |
Common source of outbreaks[66]
| Parenteral nutrition | Disinfectants |
| Disinfectants | Contrast media |
| Plasma | Heparin/anesthetic agents |
| Immunoglobulins | Multidose vials |
| Creams | Milk powder |
| Peritoneal liquids | Endoscopes/bronchoscopes |
Transmission based precautions in intensive care units[69]
| Airborne isolation | Patients suspected with TB, varicella, measles are placed in airborne isolation. Inhalation of small droplet nuclei (≤5 µm) which are suspended in air over long periods beyond 3 ft/1 m of particle source. Negative pressure room with closed doors is mandatory. N95 should be used upon entry into room. Susceptible healthcare workers (e.g., negative for IgG antibodies to varicella) caring for these patients may be replaced with nonsusceptible healthcare workers (e.g., past infection and positive for IgG antibodies to varicella). |
| Droplet isolation | Inhalation of large droplet nuclei (>5 µm) which are suspended in air within 3 ft/1 m of particle source and do not remain suspended in air over long periods. Droplet transmission requires close contact with the infected individual. It does not require special ventilation/negative pressure rooms. Conditions requiring droplet isolation: pertussis, influenza, measles, mumps, rubella, meningococci. |
| Contact isolation | Direct as well as indirect contact transmissions occur through hands of healthcare workers. Conditions requiring contact isolation: |
Vaccine recommendations for healthcare personnel[76,77]
| Hepatitis B | Three doses at 0, 1, 6 months. Protective antibody response (antiHBs) is ≥10 mIU/mL. Route of administration: intramuscular. |
| Influenza | Single-dose vaccine is recommended yearly, administered intramuscularly. Intranasal vaccine can be used as an alternative. |
| Measles, mumps, rubella | HCP born in 1957 or later: two doses of MMR vaccine given 4 weeks apart for those with no evidence of immunity or prior vaccination. |
| Varicella | Two doses given 4 weeks apart for those HCP with no evidence of immunity or past infection. Route of administration: intramuscular. |
| Diphtheria, pertussis, tetanus | Single dose of tetanus diphtheria acellular pertussis as soon as feasible without regard to the previous dose of tetanus diphtheria (Td). Pregnant HCP should be revaccinated during each pregnancy. All HCPs should then receive Td boosters every 10 years thereafter. Route of administration: intramuscular. |